E-ON-001
Glioblastoma
PreclinicalActive
Key Facts
About 199 Biotechnologies
199 Biotechnologies is an early-stage, private biotech firm developing a novel platform targeting epigenetic damage as the root cause of both cancer and aging. Its core strategy involves three synergistic programs: a lead cancer reprogramming therapy for glioblastoma (E-ON-001), a senolytic compound research program with a lead candidate (Procyanidin C1), and an affordable diagnostic service called AgeQuant. The company aims to transform treatment paradigms from destructive to restorative, offering potentially less toxic and more durable interventions for age-related diseases.
View full company profileTherapeutic Areas
Other Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Ropidoxuridine (IPdR) | Shuttle Pharmaceuticals | Phase 2 |
| LNTH-2505 | Lantheus Medical Imaging | Preclinical |
| Leronlimab | CytoDyn | Preclinical |
| Glioblastoma Moonshot | Owkin | Research |
| OPC-001 (PDC Candidate) | Oncopeptides | Phase 1/Window-of-Opportunity |
| αvβ3-targeted ADC | Xintela | Preclinical |
| Undisclosed | Biossil | Phase 2/3 |
| GLIX1 | Hemispherian | Phase 1 |
| InC01 | InCephalo Therapeutics | Pre-clinical |
| Glioblastoma Combination Therapy | JLP Health | Pre-clinical |
| ENV105 | Kairos Pharma | IND Cleared |
| LMP744 | Gibson Oncology | Phase 2 |